Barbara Schug

1.4k total citations
47 papers, 991 citations indexed

About

Barbara Schug is a scholar working on Pediatrics, Perinatology and Child Health, Pharmaceutical Science and Analytical Chemistry. According to data from OpenAlex, Barbara Schug has authored 47 papers receiving a total of 991 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pediatrics, Perinatology and Child Health, 10 papers in Pharmaceutical Science and 9 papers in Analytical Chemistry. Recurrent topics in Barbara Schug's work include Pharmaceutical studies and practices (12 papers), Drug Solubulity and Delivery Systems (9 papers) and Analytical Methods in Pharmaceuticals (9 papers). Barbara Schug is often cited by papers focused on Pharmaceutical studies and practices (12 papers), Drug Solubulity and Delivery Systems (9 papers) and Analytical Methods in Pharmaceuticals (9 papers). Barbara Schug collaborates with scholars based in Germany, United States and Netherlands. Barbara Schug's co-authors include Henning Blume, Frank Donath, Meinolf Wonnemann, E. Brendel, Stephan A. Schug, Stefan Lauer, Sina Grape, Manfred Wargenau, Katharina Erb and Róbert Hermann and has published in prestigious journals such as Journal of Controlled Release, Drugs and British Journal of Clinical Pharmacology.

In The Last Decade

Barbara Schug

46 papers receiving 931 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barbara Schug Germany 16 272 151 146 129 112 47 991
L.F. Lacey United Kingdom 19 249 0.9× 223 1.5× 133 0.9× 60 0.5× 99 0.9× 36 1.5k
Parviz Mojaverian United States 18 211 0.8× 132 0.9× 113 0.8× 103 0.8× 90 0.8× 41 886
Keith K. H. Chan United States 22 180 0.7× 247 1.6× 123 0.8× 158 1.2× 116 1.0× 63 1.2k
Kirstin Thelen Germany 20 248 0.9× 191 1.3× 259 1.8× 111 0.9× 386 3.4× 26 1.3k
Patrick K. Noonan United States 20 280 1.0× 86 0.6× 74 0.5× 50 0.4× 57 0.5× 40 901
Oliver Hatley United Kingdom 16 206 0.8× 206 1.4× 145 1.0× 76 0.6× 324 2.9× 27 952
P W Lücker Germany 15 115 0.4× 276 1.8× 82 0.6× 67 0.5× 136 1.2× 45 969
Carl‐Gunnar Regårdh Sweden 16 117 0.4× 128 0.8× 174 1.2× 164 1.3× 281 2.5× 24 1.0k
Richard H. Reuning United States 15 135 0.5× 146 1.0× 124 0.8× 143 1.1× 107 1.0× 45 809
J. Godbillon Switzerland 24 222 0.8× 107 0.7× 181 1.2× 376 2.9× 188 1.7× 61 1.3k

Countries citing papers authored by Barbara Schug

Since Specialization
Citations

This map shows the geographic impact of Barbara Schug's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Schug with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Schug more than expected).

Fields of papers citing papers by Barbara Schug

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Schug. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Schug. The network helps show where Barbara Schug may publish in the future.

Co-authorship network of co-authors of Barbara Schug

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Schug. A scholar is included among the top collaborators of Barbara Schug based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Schug. Barbara Schug is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schug, Barbara, Erem Bilensoy, Jack Cook, et al.. (2025). The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the sixth international EUFEPS/PQRI conference. European Journal of Pharmaceutical Sciences. 212. 107129–107129.
2.
3.
Balser, Sigrid, et al.. (2024). New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects. Clinical Pharmacology in Drug Development. 13(12). 1308–1316. 2 indexed citations
4.
Mehta, Minesh P., Barbara Schug, Wenlei Jiang, et al.. (2023). The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the fifth international EUFEPS/AAPS conference. European Journal of Pharmaceutical Sciences. 190. 106566–106566. 5 indexed citations
5.
Morte, Adelaida, et al.. (2022). Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared with Exelon in Healthy Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 47(4). 567–578. 6 indexed citations
6.
Chen, Mei‐Ling, Henning Blume, Minesh P. Mehta, et al.. (2018). Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence. European Journal of Pharmaceutical Sciences. 127. 24–28. 9 indexed citations
7.
Chen, Mei‐Ling, Henning Blume, Barbara M. Davit, et al.. (2017). The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference. European Journal of Pharmaceutical Sciences. 111. 153–157. 19 indexed citations
8.
Kumar, Shashi Nandar, Erik Söderlind, Anna Viridén, et al.. (2014). The influence of hydroxypropyl methylcellulose (HPMC) molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets. Journal of Controlled Release. 187. 50–58. 74 indexed citations
9.
Grape, Sina, Stephan A. Schug, Stefan Lauer, & Barbara Schug. (2009). Formulations of Fentanyl for the Management of Pain. Drugs. 70(1). 57–72. 80 indexed citations
10.
Schug, Barbara, et al.. (2009). Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. International Journal of Clinical Pharmacology and Therapeutics. 47(6). 405–412. 3 indexed citations
11.
Garbacz, Grzegorz, Olaf Kosch, Frank Donath, et al.. (2009). Characterization of the behavior of alginate-based microcapsules in vitro and in vivo. International Journal of Clinical Pharmacology and Therapeutics. 47(9). 556–563. 4 indexed citations
12.
Wonnemann, Meinolf, et al.. (2008). Comparison of two marketed nifedipine modified-release formulations: An exploratory clinical food interaction study. Clinical Therapeutics. 30(1). 48–58. 22 indexed citations
13.
Wonnemann, Meinolf, et al.. (2006). Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union. International Journal of Clinical Pharmacology and Therapeutics. 44(1). 38–48. 24 indexed citations
14.
Nassr, Nassr, Gëzim Lahu, Oliver von Richter, et al.. (2006). Lack of a pharmacokinetic interaction between steady‐state roflumilast and single‐dose midazolam in healthy subjects. British Journal of Clinical Pharmacology. 63(3). 365–370. 25 indexed citations
15.
Blume, Henning, et al.. (2005). Neue Richtlinien für die Beurteilung der Bioverfügbarkeit/Bioäquivalenz. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 48(5). 548–555. 1 indexed citations
16.
Staab, Alexander, et al.. (2003). Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses. European Journal of Pharmaceutical Sciences. 18(2). 121–128. 2 indexed citations
17.
Schug, Barbara, et al.. (2002). The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag‐time after a high fat breakfast. British Journal of Clinical Pharmacology. 53(6). 582–588. 38 indexed citations
18.
Kaunzinger, Astrid, et al.. (2002). Determination of 11-keto-boswellic acid in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 28(3-4). 729–739. 24 indexed citations
19.
Blume, Henning & Barbara Schug. (2000). Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?. European Journal of Drug Metabolism and Pharmacokinetics. 25(1). 41–48. 5 indexed citations
20.
Blume, Henning & Barbara Schug. (1999). The biopharmaceutics classification system (BCS): Class III drugs — better candidates for BA/BE waiver?. European Journal of Pharmaceutical Sciences. 9(2). 117–121. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L.F. Lacey Breakdown of academic impact, for papers by Parviz Mojaverian Breakdown of academic impact, for papers by Keith K. H. Chan Breakdown of academic impact, for papers by Kirstin Thelen Breakdown of academic impact, for papers by Patrick K. Noonan Breakdown of academic impact, for papers by Oliver Hatley Breakdown of academic impact, for papers by P W Lücker Breakdown of academic impact, for papers by Carl‐Gunnar Regårdh Breakdown of academic impact, for papers by Richard H. Reuning Breakdown of academic impact, for papers by J. Godbillon
Rankless by CCL
2026